Drug Profile

CTB 001 - Nanjing Bioheng Biotech

Alternative Names: CTB-001 - Nanjing Bioheng Biotech

Latest Information Update: 10 Jul 2025

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Nanjing Bioheng Biotech
Class Antineoplastics; CAR-T cell therapies; Gene therapies; Immunotherapies
Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

Yes - Gastric cancer
New Molecular Entity No

10 Jul 2025 CTB 001 is still in clinical trial for Gastric cancer (Nanjing Bioheng Biotech Pipeline, July 2025)
10 Jul 2025 Clinical trials in Pancreatic cancer (Parenteral) (Nanjing Bioheng Biotech Pipeline, July 2025)
28 Feb 2025 No recent reports of development identified for clinical-Phase-Unknown development in Gastric cancer (Parenteral)

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com